Skip to content
MS
OTC XLD unreviewed

OTC deficiency

Enzyme or protein defect

Ornithine transcarbamylase

Accumulates or becomes deficient

Ammonia; orotic acid HIGH

Key features

Commonest urea cycle defect; hyperammonaemia, vomiting, encephalopathy; low BUN, no megaloblastic anaemia

Management

Low-protein diet, benzoate/phenylbutyrate, arginine/citrulline

Not clinical guidance. Written from standard clinical biochemistry, not from the uploaded documents, and marked unreviewed. Teaching-level reference for study and database seeding only. It must not be used to manage a patient.

Recent literature

Europe PMC · from cache · sorted by publication date

  1. 1
    Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.

    Vicidomini A, Boisgerault F, Romano G, Guarnaccia C, Vidal P, Collaud F, Soria LR, de Sabbata G, Tedesco N, L… · 2026-06-19

    unreviewed
  2. 2
    Functional editing of the OTC locus by targeted integration with phenotype correction and restoration of endogenous expression patterns.

    Ginn SL, Doroudian F, Christina S, Chan OPY, Lucas CW, Zhu E, Yang SF, Devanapalli B, Klein AH, Scott S, Vita… · 2026-07-09

    unreviewed
  3. 3
    Long-Term Efficacy and Safety of Glycerol Phenylbutyrate in Japanese Patients With Urea Cycle Disorders: Results From a Phase 3 Switch-Over and 12-Month Extension Study.

    Wada Y, Furujo M, Kashimada K, Hamazaki T, Nyuzuki H, Ichimoto K, Kakiuchi T, Matsumoto S, Watanabe Y, Ono C,… · 2026-06-14

    open access unreviewed
  4. 4
    Infantile Spasms in Inborn Errors of Metabolism: Diagnostic and Therapeutic Considerations.

    Buraniqi E, Lee HT, Sen K, Chapman KA, Grant CL, Chen WL, Gropman AL. · 2025-11-12

    unreviewed
  5. 5
    Functional profiling of 2,193 ASS1 missense variants: Insights into variant pathogenicity and epistatic interactions in citrullinemia type I.

    Lo RS, Cromie GA, Tang M, Sirr A, Caldovic L, Morizono H, Ah Mew N, Gropman A, Dudley AM. · 2026-06-17

    open access unreviewed
  6. 6
  7. 7
    Self-Reported Health-Related Quality of Life (HRQoL) in Adults With Urea Cycle Disorders.

    Coughlin CR, Barber J, Murali CN, Members of the Urea Cycle Disorders Consortium (UCDC), Wilkening G. · 2026-05-01

    open access unreviewed
  8. 8
    Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.

    Feierman ER, Whittaker MN, Quigley A, Brooks DL, McVeigh P, Nan AX, Hsu A, Said H, Soliman OY, Giovenco R, Da… · 2026-03-31

    cited 1× unreviewed
  9. 9
  10. 10
    Xp21 Contiguous Gene Deletion Syndrome: Diagnosis, Treatment, and a Review of the Literature on a Rare Genetic Disorder

    Singin B, Donbaloğlu Z, Barsal Çetiner E, Bedel A, Çetin K, Akcan Paksoy B, Kalkan T, Akbaş H, Ünver Tuhan H,… · 2025-03-19

    cited 2× open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.